---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-011766"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:14:19.252139+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aptevo stockholders approve reverse stock split (1:15-44) and warrant issuance >19.99%

## Summary
- Proposal 1: 7,159,500 FOR, 2,477,700 AGAINST, 27,721 ABSTAIN; Board has discretion on ratio and timing.
- Proposal 2: 3,977,073 FOR, 1,495,805 AGAINST, 26,255 ABSTAIN; allows immediate exercise of warrants for >19.99% of outstanding shares.
- Reverse split ratio range 1-for-15 to 1-for-44; board will determine final ratio and effective date.
- Warrants: New Series A-2 and New Series B-2; approval under Nasdaq Listing Rule 563(d).

## SEC filing metadata
- accession: 0000950170-24-011766
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024011766/0000950170-24-011766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024011766/apvo-20240205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-011766
- JSON: https://secwatch.observer/filing/0000950170-24-011766.json
- Plain text: https://secwatch.observer/filing/0000950170-24-011766.txt

## Key facts
- Shareholder Votes
  Aptevo Therapeutics Inc. shareholders approved To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board and with such reverse stock split at the 2024-02-05 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2024-02-05
  source text: Proposal 1: To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. FOR AGAINST ABSTAIN BROKER NON-VOTES 7,159,500 2,477,700 27,721 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017024011766/0000950170-24-011766-index.htm
- Shareholder Votes
  Aptevo Therapeutics Inc. shareholders approved To approve, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Company’s outstanding common stock, par value $0.001 per share, issuable upon the exercise of New Series A-2 Warrants and New Series B-2 Warrants with the right for such potential exercise to occur imm at the 2024-02-05 meeting.
  - Outcome: passed
  - Meeting: 2024-02-05
  source text: Proposal 2: To a pprove, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Company’s outstanding common stock, par value $0.001 per share, issuable upon the exercise of New Series A-2 Warrants and New Series B-2 Warrants with the right for such potential exercise to occur immediately following the date upon which stockholders approve this proposal. FOR AGAINST ABSTAIN BROKER NON-VOTES 3,977,073 1,495,805 26,255 4,165,788
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017024011766/0000950170-24-011766-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.